Eisai and BMS partner to develop cancer antibody drug conjugate

BMS will co-develop and co-sell MORAb-202 with Eisai. Credits: © Bristol-Myers Squibb Company.

Eisai and Bristol Myers Squibb (BMS) have signed an exclusive global strategic partnership agreement to jointly develop and market the former antibody drug conjugate (ADC) MORAb-202.

MORAb-202 is a combination of Eisai’s anti-folic acid receptor alpha (FRα) antibody, farretuzumab, and its anti-cancer drug, eribulin, using an enzyme-cleavable linker.

The drug is currently undergoing Phase I clinical trials in Japan and Phase I / II clinical trials in the United States for the treatment of FRα-positive solid tumors.

Eisai plans to move MORAb-202 to the registration stage for development by next year.

Haruo Naito, CEO of Eisai, said: “MORAb-202 is a combination of in-house discovered antibodies and payload using Eisai’s advanced chemistry.

“It is characterized by the payload of eribulin, a product of our modern synthetic organic chemistry that has already contributed to patients with breast cancer and soft tissue sarcoma.”

In partnership, Eisai and BMS will co-develop and co-sell MORAb-202 in the United States, United Kingdom, Japan, China, Canada, Europe, Russia and other countries in the Asia-Pacific region.

BMS is responsible for developing and selling ADCs outside of the partnership area, and Eisai is responsible for global production and distribution.

According to the contract, Eisai will receive $ 650 million from BMS. This includes the company’s R & D (R & D) costs of $ 200 million.

In addition, Eisai is eligible to earn up to $ 2.45 billion to meet potential development, regulatory, and commercial milestones.

The two companies will share profits, R & D and marketing costs in the partnership regions, and Eisai will receive royalties from BMS for the sale of medicines outside these regions.

Giovanni Kaforio, Chairman and CEO of Bristol Myers Squibb, said: Development expertise. ”

last month, BMS and Agenus have signed the final global exclusive license agreement The latter bispecific antibody program, AGEN1777, and another private target are worth $ 1.56 billion. Eisai and BMS partner to develop cancer antibody drug conjugate

Back to top button